Opendata, web and dolomites


Disruptive GPCR Lead Discovery Platform Delivering New and Safer Therapeutics

Total Cost €


EC-Contrib. €






 PICARD project word cloud

Explore the words cloud of the PICARD project. It provides you a very rough idea of what is the project "PICARD" about.

identification    costly    off    break    safety    vital    inefficiencies    interax    earlier    successfully    outsourcing    gt    disease    paying    trial    gpcrs    variety    selective    45    biotech    fte    swiss    custom    human    risks    receptors    trials    central    efficient    paul    service    diseases    discovery    cover    investment    biology    5000    pharmacologically    screening    profiles    roi    mechanisms    revenue    company    market    society    therapeutics    2b    activation    candidates    class    patients    reaching       combination    lies    time    compounds    platform    80    efficacy    stages    services    uuml    assays    drugs    drug    eth    fast    375    designed    commercialization    gpcr    detection    nature    spin    coupled    estimate    novelty    companies    clinical    quality    milestone    picard    scherrer    functional    reducing    price    fee    play    fail    leaving    upfront    pharmaceutical    lowering    signalling    biological    implicated    payments    stream    protein    inflates   

Project "PICARD" data sheet

The following table provides information about the project.


Organization address
postcode: 5234
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Project website
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-08-01   to  2018-11-30


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INTERAX BIOTECH AG CH (VILLINGEN) coordinator 50˙000.00


 Project objective

InterAx Biotech, a Swiss company and spin-off from the ETH Zürich and the Paul Scherrer Institute has built PICARD, a unique drug discovery platform for the identification of drug candidates with improved efficacy and reduced side effects for the largest class of human receptors: The G-Protein Coupled Receptors (GPCRs). These receptors play a central role in many vital biological processes and they are implicated in a large variety of human diseases. Due to their complex nature and mechanisms that lead to the disease state, only 60 out of 375 pharmacologically relevant GPCRs have been successfully targeted by drugs, leaving >80% GPCRs without therapeutics. Bringing a drug to the market requires an investment of up to €2.2B; out of 5000 compounds only 5 will make it to the clinical trial phase and 9 out of 10 compounds fail during costly clinical trials. This inflates the price of the drugs that reach the patients, making the society paying for inefficiencies of pharmaceutical R&D. PICARD will enable better and earlier detection of safety and efficacy profiles of GPCR-targeting drugs by increasing quality and reducing costs and time-to-market of new therapeutics. The novelty of our discovery platform lies on the combination of our screening to find novel compounds, signalling Assays that cover the most common GPCR activation aspects and our Systems Biology approach leading to highly efficient and fast delivery of functional-selective compounds. We offer custom-designed PICARD services to pharmaceutical and biotech companies that are outsourcing key stages of their drug discovery process lowering risks and greatly reducing R&D costs. The revenue stream is generated both from fee per service and from long-term drug discovery partnerships with upfront and milestone payments. We estimate reaching break-even 2 years after commercialization with 45 FTE and achieving a ROI of 4.5.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PICARD" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PICARD" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

MCBD (2019)


Read More  

In-Heal (2019)

Standardised administration device for raw medical herbs

Read More  

Genetta (2019)

Pole climbing solution to improve safety at work and to prevent fatal accidents in industrial climbing

Read More